SESSION TITLE: Treatment of IPF
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 24, 2016 at 07:30 AM - 08:30 AM
PURPOSE: In a pooled analysis of data from the two replicate Phase III INPULSIS trials in patients with IPF, nintedanib significantly reduced the risk of disease progression, defined as an absolute decline in forced vital capacity (FVC) of ≥5% predicted or death, or ≥10% predicted or death, over 52 weeks versus placebo. We investigated whether nintedanib had the same effect on disease progression in subgroups defined by GAP (gender, age, physiology) stage, a composite index developed to predict prognosis in patients with IPF based on four commonly measured clinical and physiologic variables.